Heavy Domain Wall Fermions: The RBC and UKQCD charm physics program

We review the domain wall charm physics program of the RBC and UKQCD collaborations based on simulations including ensembles with physical pion mass. We summarise our current set-up and present a status update on the decay constants $f_D$, $f_{D_s}$, the charm quark mass, heavy-light and heavy-strange bag parameters and the ratio $\xi$.Comment: 8 pagers, 4 figures, conference proceedings for Lattice2017 submitted to EPJ Web of Conference

Static quarks with improved statistical precision

We present a numerical study for different discretisations of the static action, concerning cut-off effects and the growth of statistical errors with Euclidean time. An error reduction by an order of magnitude can be obtained with respect to the Eichten-Hill action, for time separations beyond 1.3 fm, keeping discretization errors small. The best actions lead to a big improvement on the precision of the quark mass Mb and F_Bs in the static approximation.Comment: 3 pages, 4 figures, Lattice2003(heavy

Towards a precision computation of f_Bs in quenched QCD

We present a computation of the decay constant f_Bs in quenched QCD. Our strategy is to combine new precise data from the static approximation with an interpolation of the decay constant around the charm quark mass region. This computation is the first step in demonstrating the feasability of a strategy for f_B in full QCD. The continuum limits in the static theory and at finite mass are taken separately and will be further improved.Comment: Lattice2003(heavy), 3 pages, 2 figure

Nitric Oxide-cGMP Signaling in Hypertension:Current and Future Options for Pharmacotherapy

For the treatment of systemic hypertension, pharmacological intervention in nitric oxide-cyclic guanosine monophosphate signaling is a well-explored but unexploited option. In this review, we present the identified drug targets, including oxidases, mitochondria, soluble guanylyl cyclase, phosphodiesterase 1 and 5, and protein kinase G, important compounds that modulate them, and the current status of (pre)clinical development. The mode of action of these compounds is discussed, and based upon this, the clinical opportunities. We conclude that drugs that directly target the enzymes of the nitric oxide-cyclic guanosine monophosphate cascade are currently the most promising compounds, but that none of these compounds is under investigation as a treatment option for systemic hypertension